StockData
Compass Therapeutics, Inc. logo

Compass Therapeutics, Inc. (CMPX) stock

CMPXNasdaqBiological Products, (No Diagnostic Substances)Fiscal year ends December 31
Financials through Q3 FY2026, quarter ended Sep 30, 2026Last filing: 10-Q on Nov 9, 2026Score 7/30
$0.77−0.05 (-5.63%)

Close on Nov 13, 2026Market cap $139.35MP/E –Yield –

Compass Therapeutics pe ratio

The price-to-earnings ratio is the share price divided by diluted earnings per share over the trailing twelve months.

No pe ratio figures for Compass Therapeutics

Compass Therapeutics has not reported this figure in its SEC filings, or the share price needed to calculate it is not available yet.

More Compass Therapeutics figures

See a number that looks wrong?